Irreversible Enzyme Inhibition

Irreversible enzyme inhibition occurs when an inhibitor forms a stable, usually covalent, bond with the enzyme, permanently abolishing its activity. Unlike reversible inhibitors, irreversible inhibitors cannot simply dissociate, so activity is restored only when the cell synthesises new enzyme.

Definition

Irreversible inhibition is the inactivation of an enzyme by an inhibitor that forms a stable, typically covalent, bond with it, producing a time-dependent and essentially permanent loss of catalytic activity.

Scope

The entry covers covalent inactivation, the special case of mechanism-based (suicide) inhibitors, and how irreversible inhibition is characterised kinetically by the rate of inactivation rather than by an equilibrium constant. It is a biochemical and methodological reference, not clinical guidance.

Core questions

• Does the inhibitor form a covalent bond, and is the loss of activity time-dependent?
• Is the inhibitor reactive on its own or activated by the enzyme's own catalytic machinery (mechanism-based)?
• How is potency described when no binding equilibrium exists?

Key concepts

• Covalent bond formation
• Time-dependent (progressive) loss of activity
• kinact/Ki potency metric
• Mechanism-based (suicide) inhibitors
• Recovery requires de novo enzyme synthesis

Key theories

Kinetics of time-dependent inactivation

Irreversible inhibition is modelled as initial reversible binding followed by an irreversible chemical step; potency is described by the second-order rate constant kinact/Ki (or kinact/KI), as formalised in the Kitz-Wilson analysis of time-dependent inactivation.

Mechanism-based (suicide) inactivation

A mechanism-based inhibitor is an unreactive substrate analogue that the enzyme converts into a reactive species at its own active site, which then forms a covalent bond and inactivates the enzyme, giving high target selectivity.

Mechanisms

An irreversible inhibitor typically binds the enzyme reversibly and then undergoes an irreversible chemical step, most often forming a covalent bond with an active-site residue, so activity is lost progressively over time and is described by an inactivation rate constant rather than an equilibrium Ki; the Kitz-Wilson treatment of acetylcholinesterase inactivation established this kinetic framework (Kitz & Wilson, 1962). Mechanism-based, or suicide, inhibitors are unreactive until the enzyme's own catalytic action converts them into a reactive intermediate at the active site, which then bonds covalently, conferring selectivity for the target enzyme (Rando, 1977). Covalent inactivation is exploited across many protease and other enzyme classes (Powers et al., 2002). Because the bond is stable, activity returns only as new enzyme is synthesised.

Clinical relevance

Several widely used drug classes act as irreversible or mechanism-based inhibitors, and their hallmark is a duration of action governed by enzyme resynthesis rather than by clearance of the drug (Copeland, 2013). This entry explains the mechanism for reference and education and does not provide dosing or treatment advice.

History

Covalent inactivation of enzymes was studied intensively through work on acetylcholinesterase and organophosphate agents, with Kitz and Wilson providing an influential kinetic analysis of time-dependent inactivation in 1962 (Kitz & Wilson, 1962). The concept of mechanism-based inhibitors, designed to be activated by the target enzyme itself, was articulated in the 1970s (Rando, 1977) and later surveyed across protease classes (Powers et al., 2002).

Key figures

• Irwin B. Wilson
• Richard Kitz
• Robert R. Rando
• James C. Powers

Seminal works

• kitz-wilson-1962
• rando-1977
• powers-2002

Frequently asked questions

Why is irreversible inhibition described by a rate instead of an inhibition constant?

Because the inhibitor forms a stable covalent bond rather than reaching a binding equilibrium, potency is captured by how fast the enzyme is inactivated, summarised by the second-order rate constant kinact/Ki.

What makes a mechanism-based (suicide) inhibitor selective?

It is chemically unreactive until the target enzyme's own catalytic machinery converts it into a reactive species at the active site, so it preferentially inactivates the enzyme that processes it.